Datapoint: FDA Postpones Review for Lilly’s Alzheimer’s Drug

March 19

The FDA will take longer than expected to make a decision on Eli Lilly & Co.’s donanemab. The Alzheimer’s drug was originally slated for an approval decision as early as this week. According to NBC News, the FDA informed Lilly that it wants more data on the drug’s safety and effectiveness. If approved, the drug would compete with Eisai Co., Ltd. and Biogen Inc.’s Leqembi (Iecanemab-irmb). The controversial therapy holds covered or better status for just 36% of all insured lives.

SOURCE: MMIT Analytics, as of 3/18/24